Narinder Singh Shargill

Vice President, Global Medical Affairs at Pulmonx

Narinder Singh Shargill, PhD has extensive work experience in the field of medical affairs, clinical affairs, and regulatory affairs. Narinder Singh has held various executive positions in several prominent companies. Narinder Singh began their career as a Senior Scientist at Scios, Inc. in 1989 and later worked as a Visiting Scientist at Glycomed, Inc. In 1992, they joined Nycomed Salutar, Inc. as a Manager of Biological Sciences. Narinder Singh then transitioned to Fusion Medical Technologies, Inc., where they served as the Director of Medical Biology, Director of Clinical Affairs, and ultimately as the Senior Director of Clinical Affairs. In 2002, they became a Senior Director of Clinical Development at Baxter. From 2003 to 2010, they worked as the Vice President of Clinical Affairs at Asthmatx, Inc. Narinder Singh then joined Boston Scientific Corp. as the Vice President of Clinical Affairs from 2010 to 2013. Subsequently, they held positions at Boston Scientific Corporation as the Vice President of Clinical Strategy & Medical Affairs - Pulmonary and at Pulmonx Corporation as the Vice President of Clinical & Regulatory Affairs and Quality Assurance. Most recently, they have been serving as the Vice President of Global Medical and Clinical Affairs at Pulmonx Corporation.

Narinder Singh Shargill, PhD pursued their early education at the University of Southampton. From 1975 to 1978, they obtained a Bachelor of Science (BSc) degree with Honors in Physiology & Biochemistry. Narinder Singh then continued their academic journey at the same university and completed their doctoral studies from 1978 to 1982, earning a PhD in Nutrition / Biochemistry.

Location

Dublin, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Pulmonx

2 followers

Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1


Industries

Employees

201-500

Links